Will the cannabinoid creme work on Psoriasis? Th
Post# of 15624
(Total Views: 302)
Posted On: 04/24/2017 9:07:20 AM
Will the cannabinoid creme work on Psoriasis?
This is the #1 question I ask myself and every shareholder should be focused on the upcoming clinical results. To be seen as effective from a patient's point-of-view, the creme will need to reduce redness, inflammation, pain and the itch. 2007 [UK] Cannabinoids may be useful for psoriasis, as THC, cannabidiol, cannabinol, and cannabigerol have been found to inhibit keratinocyte proliferation in hyperproliferating human keratinocyte cell lines.
Pain and itch are two irritating sensations sharing a lot in common.
2005 [Croatia] In a study of patients with a chronic itching that occurs in patients with advanced kidney disease, topical application of a cannabinoid creme applied twice daily for 3 weeks completely eliminated itching in 8 of 21 patients (38%). Another study of 22 patients reduced itch by 86.4% when topically administered.
Psoriasis, an autoimmune disease is characterized by an abnormally excessive and rapid growth of the epidermal layer of the skin.
Skin cells are replaced every 3–5 days in psoriasis rather than the usual 28–30 days. These changes are believed to stem from the premature maturation of keratinocytes induced by an inflammatory cascade in the dermis involving dendritic cells, macrophages, and T cells (three subtypes of white blood cells). 2013 [Germany] In mice, topical THC application effectively decreased contact allergic ear swelling and myeloid immune cell infiltration which influences inflammation. Topical THC limited myeloid immune cell recruitment by a decreasing T-cell production of interferon-y and keratinocyte production of CCL2, CCL8, and CXL10 chemokines. In terms of atopic dermatitis, the activation of CB1 receptors in mice has been found to improve epidermal barrier function, decrease Th2-mediated inflammatory response, and suppress mast cells. Mast cells (type of white blood cell) play a key role in the inflammatory process.
Although there are existing reports and studies on CBD and THC (on mice and humans), OWC's formulations will contain several active compounds from the cannabis plant, that must be fully researched and documented (but not exclusive to) the cannabinoids CBD and THC, and identifying potential therapeutic applications of the synergistic effects of these active compounds. THC may also demonstrate anti-inflammatory effects independent of CB1 and CB2 receptors, which needs to be further studied and I believe they are doing it right now.
What other skin conditions have most similar symptoms?
Acne
Basal cell carcinoma
Allergic contact dermatitis
Atopic dermatitis
Contact dermatitis
Eczema
Which interleukins is OWC focusing on?
IL1, IL2, IL3, IL8, IL10, IL13, IL15, IL17, IL20, IL23
IFN-gamma
TNF-alpha
Conclusion:
Based on the preliminary studies I believe OWC's psoriasis creme will reduce pain, inflammation and irritation in psoriasis patients. They will be able to adjust the formulations to determine the most effective syngergistic effects of several cannabinoids (not just CBD/THC). The more I look into the science, the more confident I am that this investment is well deserved and the research on the subject just isn't what it should be. OWC is on the frontier of these breakthroughs and the most valuable asset OWC will have is the intellectual property of their formulations.
Sources:
http://www.ct.gov/dcp/lib/dcp/pdf/mmp/cannabi...ocytes.pdf
http://onlinelibrary.wiley.com/doi/10.1111/all.12183/full
https://link.springer.com/article/10.1007/s00702-014-1251-x
http://www.owcpharma.com/newsroom-photos/ [CFN Interview with Dr. Yehuda Baruch]
https://www.youtube.com/watch?v=aYNgLQNpA6E [Psoriasis and beyond: targeting the IL-17 pathway]
This is the #1 question I ask myself and every shareholder should be focused on the upcoming clinical results. To be seen as effective from a patient's point-of-view, the creme will need to reduce redness, inflammation, pain and the itch. 2007 [UK] Cannabinoids may be useful for psoriasis, as THC, cannabidiol, cannabinol, and cannabigerol have been found to inhibit keratinocyte proliferation in hyperproliferating human keratinocyte cell lines.
Pain and itch are two irritating sensations sharing a lot in common.
2005 [Croatia] In a study of patients with a chronic itching that occurs in patients with advanced kidney disease, topical application of a cannabinoid creme applied twice daily for 3 weeks completely eliminated itching in 8 of 21 patients (38%). Another study of 22 patients reduced itch by 86.4% when topically administered.
Psoriasis, an autoimmune disease is characterized by an abnormally excessive and rapid growth of the epidermal layer of the skin.
Skin cells are replaced every 3–5 days in psoriasis rather than the usual 28–30 days. These changes are believed to stem from the premature maturation of keratinocytes induced by an inflammatory cascade in the dermis involving dendritic cells, macrophages, and T cells (three subtypes of white blood cells). 2013 [Germany] In mice, topical THC application effectively decreased contact allergic ear swelling and myeloid immune cell infiltration which influences inflammation. Topical THC limited myeloid immune cell recruitment by a decreasing T-cell production of interferon-y and keratinocyte production of CCL2, CCL8, and CXL10 chemokines. In terms of atopic dermatitis, the activation of CB1 receptors in mice has been found to improve epidermal barrier function, decrease Th2-mediated inflammatory response, and suppress mast cells. Mast cells (type of white blood cell) play a key role in the inflammatory process.
Although there are existing reports and studies on CBD and THC (on mice and humans), OWC's formulations will contain several active compounds from the cannabis plant, that must be fully researched and documented (but not exclusive to) the cannabinoids CBD and THC, and identifying potential therapeutic applications of the synergistic effects of these active compounds. THC may also demonstrate anti-inflammatory effects independent of CB1 and CB2 receptors, which needs to be further studied and I believe they are doing it right now.
What other skin conditions have most similar symptoms?
Acne
Basal cell carcinoma
Allergic contact dermatitis
Atopic dermatitis
Contact dermatitis
Eczema
Which interleukins is OWC focusing on?
IL1, IL2, IL3, IL8, IL10, IL13, IL15, IL17, IL20, IL23
IFN-gamma
TNF-alpha
Quote:
"Interleukins are a group of cytokines (secreted proteins and signal molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. "
*Wikipedia
"We have proven that it inhibits proliferation of keratinocytes. We are working on how does it manage in certain interleukins which cause inflammation. We are looking at the various interleukins to see what does medical cannabis, especially THC & CBD, do to those various interleukins. We have got already primary results. This study will be finished by the end of April and we can have the results published."
*CFN Interview with Dr. Yehuda Baruch, Chief Science Officer OWCP, starts at 2:57.
Conclusion:
Based on the preliminary studies I believe OWC's psoriasis creme will reduce pain, inflammation and irritation in psoriasis patients. They will be able to adjust the formulations to determine the most effective syngergistic effects of several cannabinoids (not just CBD/THC). The more I look into the science, the more confident I am that this investment is well deserved and the research on the subject just isn't what it should be. OWC is on the frontier of these breakthroughs and the most valuable asset OWC will have is the intellectual property of their formulations.
Sources:
http://www.ct.gov/dcp/lib/dcp/pdf/mmp/cannabi...ocytes.pdf
http://onlinelibrary.wiley.com/doi/10.1111/all.12183/full
https://link.springer.com/article/10.1007/s00702-014-1251-x
http://www.owcpharma.com/newsroom-photos/ [CFN Interview with Dr. Yehuda Baruch]
https://www.youtube.com/watch?v=aYNgLQNpA6E [Psoriasis and beyond: targeting the IL-17 pathway]
(1)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼